Head-to-head evidence
PF-05280586 vs SAR448501
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
PF-05280586
Marketed by Pfizer
NCT01526057 · Phase 2 · completed
The 220-participant trial was randomized, quadruple-blind, and actively controlled with European- and US-sourced rituximab. The primary pharmacokinetic comparisons met the prespecified equivalence range for both peak concentration and total drug exposure, but these were surrogate measures rather than hard clinical outcomes, supporting a moderate evidence grade.
SAR448501
Developed by Sanofi
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2029 · NCT06647069 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-05280586's landscape · SAR448501's landscape